ReviewAmerican journal of hematology2018
Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.
Review in American journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations.American journal of hematology · 2026Guideline
- The Efficacy of Pediatric-Inspired Regimens vs. Hyper-CVAD in the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.American journal of hematology · 2025Pooled it
- Intensified pegylated-asparaginase in consolidation therapy improved outcome of allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia.Annals of hematology · 2025Trial
- Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care.American journal of hematology · 2026Article
- Weight Loss During Obesity Provokes Asparaginase-Associated Liver Steatosis and Endoplasmic Reticulum Stress.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.Leukemia · 2026Article
- Upfront Immunotherapy Approaches in the Management of Adults with Acute Lymphoblastic Leukemia.Cancers · 2025Review
- Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia.JNCI cancer spectrum · 2025Article
- Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab.Blood cancer journal · 2024Review
- Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL.JCO oncology practice · 2024Article
- Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia.Cancer medicine · 2024Article
- HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia.European journal of haematology · 2024Article
- Epidemiological and clinical characteristics of adult acute lymphoblastic leukemia patients in Chile: A single-center analysis.Leukemia research reports · 2024Article
- Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment.Hematology. American Society of Hematology. Education Program · 2023Article
- Review
- Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.Cancer chemotherapy and pharmacology · 2021Article
- Article
- Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.ESMO open · 2020Review
- Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.International journal of hematologic oncology · 2020Article
- Late Effects in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia.JNCI cancer spectrum · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 12 institutions in 1 country.
Funding
Abstract
For young adults with acute lymphoblastic leukemia, pediatric-based regimens are likely to provide the following when compared to hyper-CVAD regimens: better disease control, less hospitalization time, diminished acute toxicities, decreased financial cost, more quality-adjusted life years, and fewer adverse late effects, such as infertility, myelodysplasia, and second malignant neoplasms. There are also reasons to expect less cardiac and cognitive dysfunction after pediatric regimens. The improved quality and quantity of life associated with pediatric regimens renders them preferable to hyper-CVAD regimens for the treatment of Philadelphia-negative B-precursor or T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma in young adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.